EU Buys 100 Million Additional Comirnaty Vaccine Doses

New York-based Pfizer Inc. and BioNTech SE announced they have agreed to supply an additional 100 million vaccine doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states later in 2021.

Comirnaty (Pfizer-BioNTech COVID-19 vaccine) was granted conditional marketing authorization by the European Medicines Agency to prevent COVID-19 in people from 16 years of age. 

This announcement results from the European Commission’s decision to exercise an option under its expanded Advanced Purchase Agreement signed on February 17, 2021. This new vaccine order brings the total number of Pfizer-BioNTech doses to be delivered to the EU to 600 million.

This vaccine order will be produced in BioNTech’s and Pfizer’s manufacturing sites in Europe, stated the companies.

“We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe,” commented Albert Bourla, Chairman and CEO, Pfizer, in a related press statement. “To date, we have met all of our supply commitments to the EC and we plan to deliver 250 million doses to the European Union in Q2'21, a four-fold increase on Q1’s agreed quantity.”

Located in Mainz, Germany, Biopharmaceutical New Technologies (BioNTech) is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.